MedTrace Logo

Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)

NCT01969708 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 362

Last updated 2021-06-22

Study results available
· View outcomes & findings →

Summary

SCORE2 is a multicenter, prospective, randomized, phase III clinical trial in which all participants enrolled will be followed for up to 2.5 years. SCORE2 is designed as a non-inferiority trial, with study eyes randomized to intravitreal bevacizumab (1.25 mg) every 4 weeks vs. intravitreal aflibercept (2.0 mg) every 4 weeks. SCORE2 aims to determine if bevacizumab is non-inferior to aflibercept for the treatment of macular edema associated with central retinal vein occlusion (CRVO), with the primary outcome of visual acuity measured at Month 6.

Conditions

  • Central Retinal Vein Occlusion

Interventions

DRUG

aflibercept

DRUG

bevacizumab

Sponsors & Collaborators

  • National Eye Institute (NEI)

    collaborator NIH

  • Milton S. Hershey Medical Center

    collaborator OTHER

  • University of Wisconsin, Madison

    collaborator OTHER

  • The Emmes Company, LLC

    lead INDUSTRY

Principal Investigators

  • Ingrid U Scott, M.D., M.P.H. · Penn State College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2016-11-30
Completion
2021-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01969708 on ClinicalTrials.gov